OPTIONAL
OPTIONAL
TIME HERE
Journal here
OPTIONAL
OPTIONAL
TIME HERE
Journal here
-
1. Merck & Co. received the 2020 Green Chemistry Challenge Awards for improving the process used to produce certain antiviral drugs (asymmetric phosphorylation using the chiral bicyclic imidazole catalyst).
-
2. Our bicyclic imidazazole nuleophilic catalyst (J. Am. Chem. Soc., 2010, 132, 15939-15941.) has been used and modified by Merck to prepare a chiral phosphoramidate, MK-3682, which is currently in Phase III clinical trials for treating hepatitis C. This work was published recently in Science (Science, 2017, 356, 426-430.) and highlighted by C&EN (C&EN, 2017, 95, 5.) as well as X-MOL News.
-
3. Our research about "Highly Efficient Synthesis of Qinghaosu (Artemisinin)" was reported by CCTV News (2012-08-14). This research was chosen as one of the "Top Ten Important Scientific and Technological News of China" (2012-12-28) and also chosen as one of the "Shanghai's Top Ten Scientific and Technological Achievements in 2012" (2013-05-02). The pilot plant test of 10 kilogram scale (500 L) has been successfully completed and our technology has been transferred to a company(2016-12-31).
